Vaxcyte, Inc. (PCVX)
NEUTRALFundamental
37
Price
$62.05
Market Cap
$9.16B
Part 1 · What the company is worth
Overview
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
0
Fiscal year ended 12/31/2025
Net Income
$-767M
Fiscal year ended 12/31/2025
Free Cash Flow
$-669M
Total Equity
$2.69B
Total Liabilities
$317M
Current Ratio
5.72
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$109.00
Current Price
$62.05
Margin of Safety
+43.1%
Fair Value Range
$103.55 - $114.45
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-28.5%
P/B Ratio
3.34
P/FCF
-
Gross Margin
-
ROIC
-32.1%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
11.2%
ROIC − WACC
-43.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (6)
- EPS shows upward trend
- Price CAGR 15.36%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 88% Buy
Failed (9)
- ROIC -32.1%
- P/B Ratio 3.34
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -37.6%
- Earnings Surprise avg -14.9%
- Share Dilution 11.5%
- Piotroski F-Score 1/9
Unavailable (12)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 57 |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO | 57 |
| Mr. James T. Wassil M.B.A., M.S. | Executive VP & COO | 56 |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 43 |
| Mr. Harp Dhaliwal M.B.A. | Chief Technical Operations Officer | 52 |
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research | 61 |
| Ms. Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Jeff Macdonald | Executive Director of Investor Relations | - |
| Ms. Whitney Jones | Chief People Officer | - |
| Ms. Janet Graesser | Senior Vice President of Corporate Affairs | - |
Audit Risk
3
Board Risk
6
Compensation Risk
8
Shareholder Rights Risk
8
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for PCVX, sourced from Markets Gazette.